country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-189396

Copy Link Print Information

VEGFR-2-IN-93

VEGFR-2-IN-93 is a VEGFR-2 inhibitor with an IC₅₀ of 1.79 μM. VEGFR-2-IN-93 exhibits cytotoxicity against multiple cancer cell lines and inhibits cancer cell migration. VEGFR-2-IN-93 induces G0/G1 phase arrest and apoptosis through upregulation of Bax, downregulation of Bcl-2, and activation of Caspase-3/Caspase-8. VEGFR-2-IN-93 demonstrates favorable biosafety. VEGFR-2-IN-93 can be used for research related to breast cancer, hepatocellular carcinoma, and colorectal cancer.

For research use only. We do not sell to patients.

Formula: C₂₆H₂₂N₄O₃
Molecular Weight:438.48

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

VEGFR-2-IN-93 Chemical Structure

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]

VEGFR-2

1.79 μM (IC₅₀)

Bcl-2

Bax

Caspase-3

Caspase-8

All VEGFR Isoforms :

All Bcl-2 Family Isoforms :

All Caspase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
MCF7	IC50	9.44 μM	Cytotoxic activity against human MCF-7 cells assessed as reduction in cell viability. Cytotoxic activity against human MCF-7 cells assessed as reduction in cell viability.	42569431
MDA-MB-231	IC50	9.82 μM	Cytotoxic activity against human MDA-MB-231 cells assessed as reduction in cell viability. Cytotoxic activity against human MDA-MB-231 cells assessed as reduction in cell viability.	42569431
HepG2	IC50	11.21 μM	Cytotoxic activity against human HePG-2 cells assessed as reduction in cell viability. Cytotoxic activity against human HePG-2 cells assessed as reduction in cell viability.	42569431
HCT-116	IC50	8.49 μM	Cytotoxic activity against human HCT-116 cells assessed as reduction in cell viability. Cytotoxic activity against human HCT-116 cells assessed as reduction in cell viability.	42569431
WI-38	IC50	33.47 μM	Cytotoxic activity against normal human fibroblast WI-38 cells assessed as reduction in cell viability. Cytotoxic activity against normal human fibroblast WI-38 cells assessed as reduction in cell viability.	42569431
WISH	IC50	35.23 μM	Cytotoxic activity against normal human amniotic WISH cells assessed as reduction in cell viability. Cytotoxic activity against normal human amniotic WISH cells assessed as reduction in cell viability.	42569431

In Vitro

Anti-cancerApoptosisCell Cycle RegulationOthers

Anti-cancer

VEGFR-2-IN-93 (compound 7e) exhibits potent cytotoxic activity against MCF-7, MDA-MB-231, HePG-2, and HCT-116 cancer cell lines with IC₅₀ values ranging from 8.49 to 11.21 μM, and shows good selectivity toward cancer cells relative to WI-38 and WISH normal cells^[1].
VEGFR-2-IN-93 (0-48 h) effectively inhibits the motility of HCT-116 cancer cells^[1].

Anti-cancer

Apoptosis

Cell Cycle Regulation

VEGFR-2-IN-93 induces G0/G1 phase cell cycle arrest and apoptosis in HCT-116 cells^[1].

Apoptosis

VEGFR-2-IN-93 promotes apoptosis through both intrinsic and extrinsic pathways by upregulating Bax, Caspase-3, and Caspase-8 and downregulating Bcl-2 in HCT-116 cells^[1].
VEGFR-2-IN-93 induces apoptosis in HCT-116 cells by modulating the Bax/Bcl-2 axis and activating both intrinsic and extrinsic apoptotic pathways^[1].

Others

VEGFR-2-IN-93 significantly inhibits VEGFR-2 kinase activity with an IC₅₀ of 1.79 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Chemical Information

Molecular Weight 438.48
Formula C₂₆H₂₂N₄O₃
SMILES

O=C(NC1=CC=C(/C(C)=N/NC(/C(C#N)=C/C2=CC=C(OC)C=C2)=O)C=C1)C3=CC=CC=C3
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Metwaly AM, et al. Integrated design, synthesis, biological evaluation, and computational mechanistic insights of novel benzanilide derivatives as VEGFR-2 targeted anticancer agents. RSC advances. 2026 Sep 03;16(40):46282-46300.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

VEGFR-2-IN-93

All VEGFR Isoforms

All Bcl-2 Family Isoforms

All Caspase Isoforms